Vanda Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 04/24/2024
Vanda Pharmaceuticals Stock Forecast and Price Target
Vanda Pharmaceuticals's stock is projected to advance by -46.22% from the previous closing price if it reaches the average target of $2.49 by the year's end, as reputable analysts recently projected. This potential downside is calculated on a high-end estimate of $2.79 and a low-end estimate of $2.22. If you're not interested in VNDA stock, you may be interested in its competitors.
-46.22% Downside
Vanda Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last year, Vanda Pharmaceuticals's Price has fallen from $5.05 to $0.00 – a 100.00% decrease. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach $4.99 – an increase of 100.00%. The Vanda Pharmaceuticals forecast is for Fair Value to reach $9.42 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$745.69 | Buy/Sell | $636.99 | 12.31% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$149.56 | Buy/Sell | $174.55 | 13.67% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$126.88 | Buy/Sell | $130.51 | 9.95% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$169.54 | Buy/Sell | $178.42 | 11.48% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
88.85€ | Buy/Sell | 102.80€ | 21.55% |
Vanda Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Vanda Pharmaceuticals's Revenue has fallen from $248.17M to $192.64M – a 22.38% decrease. According to 1 analysts, Vanda Pharmaceuticals's Revenue will fall by 6.98% in the next year, reaching $179.20M. Professionals believe that By 2030, Vanda Pharmaceuticals's Revenue will fall to $182.82M – a 5.10% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| KLAC Stock Forecast | KLA Corp | Outperform |
8
|
$648.21 | Buy/Sell | $644.74 | 6.60% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.12k | Buy/Sell | ¥4.74k | 10.38% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.01 | Buy/Sell | $11.59 | 22.98% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.36 | Buy/Sell | $11.73 | 5.63% |
| ITCI Stock Forecast | Intra-Cellular Therapies | Outperform |
10
|
$74.01 | Buy/Sell | $79.10 | 21.61% |
| ALKS Stock Forecast | Alkermes | Outperform |
10
|
$24.26 | Buy/Sell | $33.27 | 40.15% |
Vanda Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Vanda Pharmaceuticals's EBITDA has decreased from $30.10M to $-10.94M – a 136.35% drop. The next year looks promising for Vanda Pharmaceuticals, with analysts predicting EBITDA of $-30.87M – an increase of 182.16%. Over the next seven years, experts anticipate that Vanda Pharmaceuticals's EBITDA will grow at a rate of 651.28%.
Vanda Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
Vanda Pharmaceuticals's EBIT has decreased by 151.21% In the last three years, from $27.24M to $-13.95M. In the following year, the 1 analysts surveyed believe that Vanda Pharmaceuticals's EBIT will decrease by 30.47%, reaching $-9.70M. According to professionals, by 2030, Vanda Pharmaceuticals's EBIT will have decreased by 19.54%, falling down to $-11.22M.
Vanda Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, Vanda Pharmaceuticals's EPS has fallen from $0.58 to $0.00 – a 100.00% decrease. In the next year, analysts are expecting an increase in EPS, predicting it will reach $-0.17 – an increase of 100.00%. The Vanda Pharmaceuticals forecast is for EPS to reach $-0.13 or grow by 100.00%.
Site Navigation
.jpg)